Testosterone for 'late-onset hypogonadism' in men?

Drug and Therapeutics Bulletin

Volumn 48, Issue 6, 2010, Pages 69-72

[No Author Info available]

Author keywords

[No Author keywords available]

Indexed keywords

GONADORELIN AGONIST; PLACEBO; TESTOSTERONE; ANDROGEN;

ACNE; AGING; ANDROGEN DEFICIENCY; ANDROGEN THERAPY; ANDROPAUSE; AZOOSPERMIA; BODY COMPOSITION; CARDIOVASCULAR RISK; COGNITION; CONGESTIVE HEART FAILURE; DEPRESSION; DISEASE COURSE; EDEMA; EPILEPSY; ERECTILE DYSFUNCTION; GYNECOMASTIA; HUMAN; HYPERTENSION; HYPOGONADISM; ISCHEMIC HEART DISEASE; LATE ONSET HYPOGONADISM; LIBIDO; MALE; MIGRAINE; MUSCLE MASS; MUSCLE STRENGTH; ONSET AGE; PRIAPISM; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SEXUAL FUNCTION; SIDE EFFECT; SKIN IRRITATION; SLEEP APNEA SYNDROME; SODIUM RETENTION; TESTOSTERONE RELEASE; THERAPY EFFECT; TREATMENT CONTRAINDICATION; TREATMENT INDICATION; URINARY TRACT OBSTRUCTION; ARTICLE; FEMALE; RISK FACTOR; TREATMENT OUTCOME;

ANDROGENS; BODY COMPOSITION; DEPRESSIVE DISORDER; FEMALE; HUMANS; HYPOGONADISM; LIBIDO; MALE; QUALITY OF LIFE; RISK FACTORS; TESTOSTERONE; TREATMENT OUTCOME;

EID: 78349247957     PISSN: 00126543     EISSN: 17555248     Source Type: Journal    
DOI: 10.1136/dtb.2010.01.0004     Document Type: Review

References (47)

1. Restandol testocaps 40mg capsule, soft. Summary of product characteristics, UK. Organon Laboratories Ltd, September 2007.
2. Sustanon 250. Summary of product characteristics, UK. Organon Laboratories Ltd, January 2006.
3. Testosterone implant 100mg. Summary of product characteristics, UK. Organon Laboratories Ltd, October 2005.
4. Nebido 1000mg/4ml, solution for injection. Summary of product characteristics, UK. Bayer plc, November 2008.
5. Andropatch 2.5mg. Summary of product characteristics, UK. SmithKline Beecham plc, September 2007.
6. Tostran 2% gel. Summary of product characteristics, UK. ProStrakan Ltd, October 2006.
7. Testim gel. Summary of product characteristics, UK. Ferring Pharmaceuticals Ltd, July 2009.
8. Testogel. Summary of product characteristics, EU. Laboratoires Besins International, November 2006.
9. Perheentupa A, Huhtaniemi I. Does the andropause exist? Nat Clin Pract Endocrinol Metab 2007; 3: 670-1. (Pubitemid 47463706)
10. Griffin JE, Wilson JD. The testis: gonad and growth. In: Besser GM, Thorner MO (Eds). Comprehensive Clinical Endocrinology. Third edition. Edinburgh: Elsevier Science Ltd [Mosby], 2002.
11. Seidman SN. Normative hypogonadism and depression: does 'andropause' exist? Int J Impot Res 2006; 18: 415-22.
12. Kaushik M et al. Cardiovascular disease and androgens: a review. Int J Cardiol 2009; November 16 [Epub ahead of print].
13. Bhasin S et al. Testosterone therapy in adult men with androgen deficiency syndromes: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab 2006; 91: 1995-2010. (Pubitemid 43854972)
14. Feldman HA et al. Age trends in the level of serum testosterone and other hormones in middle-aged men: longitudinal results from the Massachusetts male aging study. J Clin Endocrinol Metab 2002; 87: 589-98. (Pubitemid 34158223)
15. Beauchet O. Testosterone and cognitive function: current clinical evidence of a relationship. Eur J Endocrinol 2006; 155: 773-81. (Pubitemid 46040613)
16. Harman SM et al. Longitudinal effects of aging on serum total and free testosterone levels in healthy men. Baltimore Longitudinal Study of Aging. J Clin Endocrinol Metab 2001; 86: 724-31. (Pubitemid 32207487)
17. Shores MM et al. Low serum testosterone and mortality in male veterans. Arch Intern Med 2006; 166: 1660-5. (Pubitemid 44232378)
18. Lapauw B et al. The decline of serum testosterone levels in community-dwelling men over 70 years of age: descriptive data and predictors of longitudinal changes. Eur J Endocrinol 2008; 159: 459-68.
19. Kaufman JM, Vermeulen A. The decline of androgen levels in elderly men and its clinical and therapeutic implications. Endocr Rev 2005; 26: 833-76. (Pubitemid 41428540)
20. Shores MM et al. Low testosterone levels predict incident depressive illness in older men: effects of age and medical morbidity. J Clin Psychiatry 2005; 66: 7-14.
21. Travison TG et al. The relative contributions of aging, health, and lifestyle factors to serum testosterone decline in men. J Clin Endocrinol Metab 2007; 92: 549-55.
22. Mah PM, Wittert GA. Obesity and testicular function. Mol Cell Endocrinol 2010; 316: 180-6.
23. Kanayana G et al. Testosterone supplementation for depressed men: current research and suggested treatment guidelines. Exp Clin Psychopharmacol 2007; 15: 529-38.
24. Black AM et al. The reliability of clinical and biochemical assessment in symptomatic late-onset hypogonadism: can a case be made for a 3-month therapeutic trial? BJU Int 2004; 94: 1066-70. (Pubitemid 39577095)
25. World Health Organization, 2007. International statistical classification of diseases and related health problems, 10th Revision [online]. Available: http://apps.who.int/classifications/apps/icd/icd10online/ [Accessed 20 May 2010].
26. Araujo AB et al. Sex steroids and all-cause and cause-specific mortality in men. Arch Intern Med 2007; 167: 1252-60. (Pubitemid 46998496)
27. Araujo AB et al. Prevalence of symptomatic androgen deficiency in men. J Clin Endocrinol Metab 2007; 92: 4241-7. (Pubitemid 350074738)
28. Bassil N et al. The benefits and risks of testosterone replacement therapy: a review. Ther Clin Risk Manag 2009; 5: 427-48.
29. Spetz AC et al. Testosterone correlated to symptoms of partial androgen deficiency in aging men (PADAM) in an elderly Swedish population. Menopause 2007; 14: 999-1005.
30. Morley JE et al. Validation of a screening questionnaire for androgen deficiency in aging males. Metab Clin Exp 2000; 49: 1239-42.
31. Blümel JE et al. Is the Androgen Deficiency of Aging Men (ADAM) questionnaire useful for the screening of partial androgenic deficiency of aging men? Maturitas 2009; 63: 365-8.
32. Moore C et al. The Aging Males' Symptoms scale (AMS) as outcome measure for treatment of androgen deficiency. Eur Urol 2004; 46: 80-7. (Pubitemid 38748514)
33. Travison TG et al. The natural history of symptomatic androgen deficiency in men: onset, progression, and spontaneous remission. J Am Geriatr Soc 2008; 56: 831-9. (Pubitemid 351652412)
34. Morales A et al. Adding to the controversy: pitfalls in the diagnosis of testosterone deficiency syndromes with questionnaires and biochemistry. Aging Male 2007; 10: 57-65. (Pubitemid 46904746)
35. Rosner W et al. Position statement: utility, limitations, and pitfalls in measuring testosterone: an Endocrine Society position statement. J Clin Endocrinol Metab 2007; 92: 405-13.
36. Sharma V, Perros P. The management of hypogonadism in aging male patients. Postgrad Med 2009; 121: 113-21.
37. Wang C et al. Investigation, treatment and monitoring of late-onset hypogonadism in males: ISA, ISSAM, EAU, EAA and ASA recommendations. Eur J Endocrinol 2008; 159: 507-14.
38. Chubb SA et al. Lower sex hormone-binding globulin is more strongly associated with metabolic syndrome than lower total testosterone in older men: the Health in Men Study. Eur J Endocrinol 2008; 158: 785-92. (Pubitemid 351837366)
39. Casey R. The use of hormonal therapy in 'andropause': the con side. Can Urol Assoc J 2008; 2: 47-8.
40. Gray PB et al. Dose-dependent effects of testosterone on sexual function, mood, and visuospatial cognition in older men. J Clin Endocrinol Metab 2005; 90: 3838-46.
41. Ottenbacher KJ et al. Androgen treatment and muscle strength in elderly men: a meta-analysis. J Am Geriatr Soc 2006; 54: 1666-73.
42. Miner MM, Seftel AD. Testosterone and ageing: what have we learned since the Institute of Medicine report and what lies ahead? Int J Clin Pract 2007; 61: 622-32. (Pubitemid 46449829)
43. Steidle C et al. AA2500 testosterone gel normalizes androgen levels in aging males with improvements in body composition and sexual function. J Clin Endocrinol Metab 2003; 88: 2673-81.
44. Makhsida N et al. Hypogonadism and metabolic syndrome: implications for testosterone therapy. J Urol 2005; 174: 827-34. (Pubitemid 41140604)
45. Page ST et al. Exogenous testosterone (T) alone or with finasteride increases physical performance, grip strength, and lean body mass in older men with low serum T. J Clin Endocrinol Metab 2005; 90: 1502-10.
46. Rhoden EL, Morgentaler A. Influence of demographic factors and biochemical characteristics on prostate-specific antigen (PSA) response to testosterone replacement therapy. Int J Impot Res 2006; 18: 201-5. (Pubitemid 43336489)
47. Calof OM et al. Adverse events associated with testosterone replacement in middle-aged and older men: a meta-analysis of randomized, placebo-controlled trials. J Gerontol A Biol Sci Med Sci 2005; 60: 1451-7.